In this study, we investigated the therapeutic effects of the nanobioconjugate carrying a combination of EGFR AON and 2C5 anti-tumor mAb along with TfR as active targeting for EGFR-positive triple negative breast cancer treatment. The gene discussed is EGFR; the disease is triple-negative breast carcinoma.